Comment: Analysis of Severe Adverse Events Related to the Use of Mifepristone as an Abortifacient

Guidance for industry: establishing pregnancy exposure registries. Rockville, MD: US Department of Health and Human Services, FDA, CDER, CBER. Page 3. www.fda.gov/cder/guidance/3626fnl.pdf (accessed 2006 Mar 21).

Pons JC , Imbert MC , Elefant E , Roux C , Herschkorn P , Papiemik E. Development after exposure to mifepristone in early pregnancy (letter). Lancet 1991;338:763.

Food and Drug Administration, Department of Health and Human Services. Federal Register;62(104):29539 www.fda.gov/cder/guidance/iche8.htm (accessed 2006 Mar 21).

www.fda.gov/womens/registries/registries.html (accessed 2006 Mar 21).

Guidance for industry: establishing pregnancy exposure registries. Rockville, MD: US Department of Health and Human Services, FDA, CDER, CBER. Page 13. www.fda.gov/cder/guidance/3626fnl.pdf (accessed 2006 Mar 21).